Clareo Health | To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients with COPD, 40 to 80 years of age
All patients must have a diagnosis of COPD and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a post-bronchodilator 30% \</= Forced Expiratory Volume (FEV1) \</= 65% of predicted normal. And a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) \<70%.
You may not be if
Patients with a significant respiratory disease other than COPD. A significant disease is defined as a disease which, in the opinion of the investigator
Patients with a medical disorder, condition or history of such that would impair the patients ability to participate or complete this study in the opinion of the investigator, patients who have mental disorder which is inappropriate to communal living in a participation in a clinical study, who have no ability to give informed consent, or who have physical disability
Patients with a history of CF
Patients with clinically evident bronchiectasis
Patients with a history of asthma
Patients who have undergone thoracotomy with pulmonary resection
Patients with relevant conspicuous findings in medical history and pre-study examination not related to the underlying disease
